Clene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Clene Inc. (CLNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 674.03 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 344.83K shares, a 414.87% increase year-over-year.
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 329.20K shares, a 3.70% increase year-over-year.
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 149.75K shares, a 163.54% increase year-over-year.
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 369.56K shares, a 123.81% increase year-over-year.
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 903.74K shares, a 7.37% decline from fiscal 2024.
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 975.67K shares, a 86.17% decline from fiscal 2023.
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 7.05M shares, a 10.70% increase from fiscal 2022.
- Clene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 6.37M shares, a 64.17% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 344.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 674.03K shares 10-Q · filed 2026-08-14 | 823.78K shares derived: sum of 3 quarters · filed 2026-08-14 | 1.19M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 329.20K shares 10-Q · filed 2026-05-14 | 478.95K shares derived: sum of 2 quarters · filed 2026-05-14 | 848.51K shares derived: sum of 3 quarters · filed 2026-05-14 | 915.49K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 149.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 519.31K shares derived: sum of 2 quarters · filed 2026-03-17 | 586.29K shares derived: sum of 3 quarters · filed 2026-03-17 | 903.74K shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 369.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 436.54K shares derived: sum of 2 quarters · filed 2025-11-13 | 753.99K shares 10-Q · filed 2025-11-13 | 810.81K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 66.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 384.43K shares 10-Q · filed 2025-08-14 | 441.25K shares derived: sum of 3 quarters · filed 2025-08-14 | 606.38K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 317.45K shares 10-Q · filed 2025-05-07 | 374.28K shares derived: sum of 2 quarters · filed 2025-05-07 | 539.40K shares derived: sum of 3 quarters · filed 2025-05-07 | 1.01M shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 56.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 221.95K shares derived: sum of 2 quarters · filed 2025-03-24 | 695.60K shares derived: sum of 3 quarters · filed 2025-03-24 | 975.67K shares 10-K · filed 2025-03-24 |
| 2024-09-30 | 165.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 638.78K shares derived: sum of 2 quarters · filed 2024-11-13 | 918.85K shares 10-Q · filed 2024-11-13 | 1.28M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 473.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 753.72K shares 10-Q · filed 2024-08-07 | 1.12M shares derived: sum of 3 quarters · filed 2024-08-07 | 1.45M shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 280.07K shares 10-Q · filed 2024-05-08 | 643.01K shares derived: sum of 2 quarters · filed 2024-05-08 | 971.91K shares derived: sum of 3 quarters · filed 2024-05-08 | 6.26M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 362.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 691.84K shares derived: sum of 2 quarters · filed 2024-03-13 | 5.98M shares derived: sum of 3 quarters · filed 2024-03-13 | 7.05M shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 328.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 5.61M shares derived: sum of 2 quarters · filed 2023-11-07 | 6.69M shares 10-Q · filed 2023-11-07 | 10.20M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 5.28M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 6.36M shares 10-Q · filed 2023-08-14 | 9.87M shares derived: sum of 3 quarters · filed 2023-08-14 | 9.98M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 1.08M shares 10-Q · filed 2023-05-12 | 4.58M shares derived: sum of 2 quarters · filed 2023-05-12 | 4.69M shares derived: sum of 3 quarters · filed 2023-05-12 | 4.96M shares derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | 3.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | 3.62M shares derived: sum of 2 quarters · filed 2023-03-13 | 3.88M shares derived: sum of 3 quarters · filed 2023-03-13 | 6.37M shares 10-K · filed 2023-03-13 |
| 2022-09-30 | 109.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 372.90K shares derived: sum of 2 quarters · filed 2022-11-07 | 2.87M shares 10-Q · filed 2022-11-07 | 4.17M shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 263.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 2.76M shares 10-Q · filed 2022-08-15 | 4.06M shares derived: sum of 3 quarters · filed 2022-08-15 | 4.31M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 2.49M shares 10-Q · filed 2022-05-09 | 3.80M shares derived: sum of 2 quarters · filed 2022-05-09 | 4.05M shares derived: sum of 3 quarters · filed 2022-05-09 | |
| 2021-12-31 | 1.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 1.56M shares derived: sum of 2 quarters · filed 2022-03-11 | 3.88M shares 10-K · filed 2022-03-11 | |
| 2021-09-30 | 251.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 2.57M shares 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | 2.32M shares 10-Q · filed 2021-08-09 | |||
| 2020-12-31 | 270.56K shares 10-K · filed 2021-03-29 | |||
| 2019-12-31 | 1.44M shares 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |